Ketamine, an NMDA receptor antagonist has been shown to induce aberrant behaviour
phenotypes in rodents, some of which are known to simulate the behaviour abnormalities …

Lack of appropriate animal models simulating core behavioural aspects of human psychosis
is a major limitation in schizophrenia research. The use of drugs, that is believed to act …

Background: Schizophrenia has been associated with disturbances of thalamic functioning.
In light of recent evidence suggesting a significant impact of the glutamatergic system on key …

Background: The observation that N-methyl-D-aspartate glutamate receptor (NMDAR)
antagonists such as ketamine transiently induce schizophrenia-like positive, negative and …

Previously, it was shown that subchronic application of the NMDA receptor antagonist
ketamine (Ket) induces schizophrenia-related alterations, eg decreased non-aggressive …

Rationale Ketamine, a non-competitive NMDA receptor antagonist, induces acute effects
resembling the positive, negative and cognitive symptoms of schizophrenia. Chronic use …

Rationale: The dopamine hypothesis is the most widely investigated theory underlying
schizophrenia and the mechanisms of action for antipsychotic drugs. However, recent …

Noncompetitive N-methyl-D-aspartate (NMDA) antagonists such as ketamine represent
useful pharmacological tools to model, in both healthy humans and rodents, behavioral and …

Schizophrenia is a chronic debilitating psychiatric disorder affecting as many as 1% of the
population worldwide. Unfortunately, its etiology and pathophysiology are poorly defined …

The observation that antagonists of the N-methyl-D-aspartate receptor (NMDAR), such as
phencyclidine (PCP) and ketamine, transiently induce symptoms of acute schizophrenia had …